About MV BioTherapeutics

We are a Swiss microbiome biotherapeutics company, a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona.

The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications:

1. ApyraVax with the lead indication of Clostridioides difficile infection
2. ApyraMed with lead indications as immune modulator in cancer and beneficial for the gut ecosystem

Research experiments and preclinical trials are performed in the research lab hosted at IRB.  The company is looking for seed funding in order to move forward as a fully operational company into clinics with the main indications.

MV BioTherapeutics ApyraMed ApyraVax
Fabio Grassi - MV BioTherapeutics ApyraVax ApyraMed

About the founder

Fabio Grassi, M.D., Ph.D.

Fabio Grassi, is a leading expert in mucosal immunology.  He earned his degree in Medicine at the University of Pavia and a Ph.D. in Microbiology at the University of Milan. He joined the Institute for Research in Biomedicine in Bellinzona in 2002 as Head of the Mucosal Immunology lab. His research is focused on understanding mechanisms regulating the mucosal adaptive immune response as well as mutualism with intestinal commensals. He is also full professor of Biology at the Medical School of the University of Milan.

Company history

2014

Discovery

Discovery of adenosine triphosphate (ATP) as a crucial inter-kingdom signaling molecule between the intestinal microbiota and host immune system.

2017

Patent

Patent filing in the US, Europe and other major markets on the apyrase (Apy) technology platform.

2017

StartCup Ticino

Second place as EXEAD project at StartCup Ticino (now Boldbrain), the yearly contest promoting Startups with the support of the Canton TicinoFondazione Agire and EFG.

2018

Incorporation

MicroVaccines SA is incorporated with the goal to move forward into clinical trials with the lead candidates.

2019

License

MV obtains the exclusive and global license of the Apy technology platform from IRB.

2020

Innosuisse coaching, new company name

MV is approved for core coaching by Innosuisse.

Having more indications and future applications, changed the too specific company name from MicroVaccines to MV BioTherapeutics.

2020

Fund raising

EU patent on Apy technology platform is granted as also in other countries.